Table 2.
Grade 3 or more adverse events in COVID-19 patients who received remdesivir treatment.
| Grade 3 | Grade 4 | Grade 5 | |
|---|---|---|---|
| Infection | 17 | 8 | 2 |
| Septic shock | 0 | 3 | 0 |
| Aspiration | 4 | 1 | 0 |
| Hyperkalepia | 2 | 1 | 0 |
| Hypokalemia | 0 | 1 | 0 |
| Hypernatremia | 0 | 1 | 0 |
| Hyponatremia | 0 | 1 | 0 |
| Aspartate aminotransferase increase | 1 | 1 | 0 |
| Alanine aminotransferase increase | 2 | 1 | 0 |
| γ-Glutamyltransferase increase | 2 | 0 | 0 |
| Blood bilirubin increase | 1 | 0 | 0 |
| Alkaline phosphatase increase | 1 | 0 | 0 |
| Serum amylase increase | 3 | 3 | 0 |
| Lipase increase | 16 | 6 | 0 |
| Pancreatitis | 3 | 0 | 0 |
| Pneumonitis | 1 | 1 | 0 |
| Pneumothorax | 2 | 0 | 0 |
| Bleeding | 1 | 0 | 0 |
| Upper gastrointestinal hemorrhage | 1 | 0 | 0 |
| Lower gastrointestinal hemorrhage | 1 | 0 | 0 |
| Gastric ulcer | 1 | 0 | 0 |
| Diarrhea | 1 | 0 | 0 |
| Acute kidney injury | 3 | 0 | 0 |
| Stroke | 1 | 0 | 0 |
| Thromboembolic event | 1 | 0 | 0 |
| Rash maculo-papular | 1 | 0 | 0 |
| Shingles | 1 | 0 | 0 |
| Delirium | 11 | 1 | 0 |
| Psychosis | 1 | 1 | 0 |
Among the adverse events (AEs) assessed using CTCAE version 5, AEs of Grade 3 or higher are described.